Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival

Figure 1

Relapse-free survival in the TIL + IL-2 group: this difference was not significant (𝑃=0.45; log-rank test); 16.7 years of median followup.